NCT02785185

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion (0.01% Halobetasol Propionate) to Ultravate® (Halobetasol Propionate) Cream, in the Treatment of Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Bausch Health Americas, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.

Detailed description

A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion (0.01% halobetasol propionate) to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	IDP-122 Vehicle Lotion	Vehicle
DRUG	IDP-122 Vehicle Cream	Vehicle
DRUG	IDP-122 Lotion	Lotion
DRUG	Ultravate Cream	Cream

Timeline

• Start date: 2016-06-01
• Primary completion: 2016-12-02
• Completion: 2017-01-01
• First posted: 2016-05-27
• Last updated: 2020-08-27
• Results posted: 2020-08-27

Locations

13 sites across 1 country: United States